Molecular Psychiatry Impact Factor

The first signal is status. Molecular Psychiatry is not operating as a broad clinical psychiatry journal. It sits in the upper tier of journals where psychiatric relevance has to be paired with biological weight.

The second signal is durability. The five-year JIF of 11.8 is above the current JIF, which suggests the journal's strongest papers continue to matter beyond the short citation window.

The third signal is normalized performance. The JCI of 2.21 is strong. That matters because psychiatry overlaps with neuroscience, molecular biology, imaging, genetics, and psychopharmacology, all of which have different citation cultures. A JCI at this level says the journal is beating category baseline after normalization.

The fourth signal is cleanliness. The JIF without self-cites is 9.7, which stays close to the headline number. That is another reason to treat the metric as real rather than inflated.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 9.21 in 2023 to 10.52 in 2024. The broader pattern is useful too. This is not a journal with a weak baseline and one accidental spike. It has spent a decade in a high citation band.

That fits the editorial identity. Biological psychiatry papers with strong mechanistic and translational consequence can travel across multiple readerships, and Molecular Psychiatry benefits from that cross-lane relevance.

The most common mistake is to read 10.1 and assume the journal is just a very strong psychiatry title in the generic sense.

That misses the real screen. The official journal information page still defines the journal around work that elucidates biological mechanisms underlying psychiatric disorders and their treatment, with emphasis at the interface of pre-clinical and clinical research.

That means the impact factor can flatter the wrong manuscripts. Papers often miss here when they are:

• clinically interesting but biologically shallow
• mechanistically sophisticated but psychiatrically under-consequential
• biomarker-heavy and statistically polished, but too associative to feel decisive

The number says the journal is important. It does not say that standard psychiatry research with a molecular garnish belongs here.

In our pre-submission review work with manuscripts targeting Molecular Psychiatry, three patterns generate the most consistent desk-rejection outcomes.

The biology is present, but the psychiatric consequence stays vague. We often see strong molecular or imaging work that never makes the disorder-level or treatment-level implication convincing enough.

The psychiatric question is strong, but the mechanistic evidence is too thin. Clinically interesting cohort and biomarker studies can still feel too associative when the biological chain is weak.

The paper sits awkwardly between preclinical and clinical without earning the bridge. The journal likes interface work, but not every paper that contains both domains actually integrates them.

If that sounds familiar, a Molecular Psychiatry submission readiness review is usually more useful than another round of language cleanup.

The official Nature journal information page adds a signal the JCR row alone does not. It currently presents the journal as high-impact work at the interface of pre-clinical and clinical research, spanning cellular, molecular, integrative, clinical, imaging, and psychopharmacology levels.

That matters because it clarifies the metric's meaning. This is not simply a psychiatry number. It is a number earned by papers that can draw attention across psychiatry, neuroscience, and molecular biology.

The open secondary metrics support that read:

• Scopus impact score 10.52
• SJR 4.022
• h-index 261

Together they point to a journal with broad scientific influence, not just category prestige.

The impact factor does not tell you whether the translational bridge is strong enough, whether the biomarker logic is decisive enough, or whether the manuscript's better owner is JAMA Psychiatry, Biological Psychiatry, or a neuroscience journal.

That is the main trap. The number can make the journal seem broader and more permissive than it actually is.